Analysts Offer Insights on Healthcare Companies: Aldeyra Therapeutics (ALDX) and Pacira Pharmaceuticals (PCRX)


There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aldeyra Therapeutics (ALDX) and Pacira Pharmaceuticals (PCRX) with bullish sentiments.

Aldeyra Therapeutics (ALDX)

JonesTrading analyst Matthew Cross maintained a Buy rating on Aldeyra Therapeutics today and set a price target of $34. The company’s shares opened today at $6, close to its 52-week low of $4.99.

Cross commented:

“We maintain our BUY rating and 12-month price target of $34.00/share. What’s in store for dry eye and Aldeyra’s deepening pipeline in 2H:19. With enrollment now completed for RENEW Part 1, we believe it is an appropriate time to set expectations for what may be announced in Q4 upon completion. Part 1 is formally designed to inform powering, dosing methodology, and potentially endpoints for the confirmatory Part 2 in dry eye, with substantive topline results reserved for after the completion of Part 2.”

According to TipRanks.com, Cross has 0 stars on 0-5 star ranking scale with an average return of -10.9% and a 28.7% success rate. Cross covers the Healthcare sector, focusing on stocks such as Catalyst Biosciences Inc, Actinium Pharmaceuticals, and Abeona Therapeutics.

Currently, the analyst consensus on Aldeyra Therapeutics is a Strong Buy with an average price target of $27.20.

See today’s analyst top recommended stocks >>

Pacira Pharmaceuticals (PCRX)

Wedbush analyst Liana Moussatos reiterated a Buy rating on Pacira Pharmaceuticals today and set a price target of $85. The company’s shares opened today at $45.50.

According to TipRanks.com, Moussatos is ranked 0 out of 5 stars with an average return of -11.8% and a 27.4% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Allena Pharmaceuticals Inc, and Aquestive Therapeutics Inc.

Currently, the analyst consensus on Pacira Pharmaceuticals is a Moderate Buy with an average price target of $68.50.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts